ADMA Biologics, Inc. and Bausch Health Companies Inc.: SG&A Spending Patterns Compared

SG&A Spending: ADMA vs. Bausch Health

__timestampADMA Biologics, Inc.Bausch Health Companies Inc.
Wednesday, January 1, 201448238692026300000
Thursday, January 1, 201567459682682700000
Friday, January 1, 201684947422810000000
Sunday, January 1, 2017180928352582000000
Monday, January 1, 2018225029222473000000
Tuesday, January 1, 2019259107572554000000
Wednesday, January 1, 2020350508172367000000
Friday, January 1, 2021428968892624000000
Saturday, January 1, 2022524580242625000000
Sunday, January 1, 2023590200002917000000
Loading chart...

Igniting the spark of knowledge

SG&A Spending Patterns: A Tale of Two Companies

In the ever-evolving landscape of the biopharmaceutical industry, understanding the financial strategies of key players is crucial. ADMA Biologics, Inc. and Bausch Health Companies Inc. offer a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses. Over the past decade, ADMA Biologics has seen a staggering increase in SG&A spending, growing by over 1,100% from 2014 to 2023. This reflects their aggressive expansion and investment in operational capabilities. In contrast, Bausch Health Companies Inc. has maintained a more stable SG&A expenditure, with a modest 44% increase over the same period. This stability suggests a focus on efficiency and cost management. As we delve into these financial narratives, it becomes clear that each company's approach to SG&A spending is a reflection of its broader strategic priorities.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025